Omeros Corporation (OMER) Price Target Increased to $8.63 by Analysts at S&P Equity Research
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research downgraded Omeros Corporation from a hold rating to a sell rating in a research note on Wednesday, October 12th. Wedbush reiterated an outperform rating and set a $56.00 price target (down previously from $62.00) on shares of Omeros Corporation in a research note on Thursday, August 11th. Cantor Fitzgerald reiterated a buy rating and set a $21.00 price target on shares of Omeros Corporation in a research note on Wednesday, August 10th. Maxim Group cut their price target on Omeros Corporation from $30.00 to $19.00 and set a buy rating for the company in a research note on Wednesday, August 10th. Finally, FBR & Co reiterated an outperform rating and set a $38.00 price target on shares of Omeros Corporation in a research note on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $32.45.
Shares of Omeros Corporation (NASDAQ:OMER) traded down 1.645% during trading on Monday, hitting $7.475. The stock had a trading volume of 158,801 shares. Omeros Corporation has a 52 week low of $7.26 and a 52 week high of $16.80. The company’s market capitalization is $293.72 million. The company’s 50 day moving average price is $10.51 and its 200 day moving average price is $11.63.
Omeros Corporation (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.18. The company had revenue of $10 million for the quarter, compared to analyst estimates of $9.80 million. Omeros Corporation’s revenue for the quarter was up 212.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.44) EPS. Analysts predict that Omeros Corporation will post ($1.55) earnings per share for the current year.
In related news, VP Marcia S. Kelbon sold 16,000 shares of Omeros Corporation stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total value of $174,560.00. Following the sale, the vice president now owns 179,597 shares of the company’s stock, valued at approximately $1,959,403.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Marcia S. Kelbon sold 15,900 shares of Omeros Corporation stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $11.56, for a total transaction of $183,804.00. Following the completion of the sale, the vice president now directly owns 179,497 shares in the company, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the company. Ingalls & Snyder LLC bought a new stake in Omeros Corporation during the second quarter worth approximately $46,441,000. Bank of Montreal Can bought a new stake in Omeros Corporation during the second quarter worth approximately $17,641,000. BlackRock Fund Advisors boosted its stake in shares of Omeros Corporation by 0.7% in the first quarter. BlackRock Fund Advisors now owns 1,471,968 shares of the biopharmaceutical company’s stock worth $22,580,000 after buying an additional 10,605 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Omeros Corporation by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,430,125 shares of the biopharmaceutical company’s stock worth $15,045,000 after buying an additional 32,401 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Omeros Corporation by 16.8% in the second quarter. State Street Corp now owns 881,993 shares of the biopharmaceutical company’s stock worth $9,274,000 after buying an additional 126,595 shares during the last quarter. 48.04% of the stock is currently owned by institutional investors.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.